Cell Therapy Market Size, Share, & Trends Analysis Report By Therapy Type (Autologous, Allogenic), By Therapeutic Area (Oncology, CVD, Dermatology), By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global cell therapy market size was valued at USD 4.77 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 16.5% from 2023 to 2030. The market for cell therapy is constantly growing to include new cell types, which presents a significant opportunity for companies to strengthen their market positions. As a result, during the past few years, there has been a dramatic increase in the number of companies engaged in the development of cell therapies. The rise in funding for cell therapy clinical studies, the adoption of useful guidelines for cell therapy manufacturing, and the success of novel products are some of the major factors influencing the growth in the number of companies in the market.

Additionally, a reduction in the cost of stem cell therapies has led to a rise in consumer interest. The development of cell banking facilities and the ensuing growth in cell manufacturing, storage, and characterization have enhanced the market's ability to handle large volumes on a global scale. This has directly contributed to the market's increased revenue generation over the previous few years.

An increase in the number of clinical trials can be attributed to the presence of private and government funding agencies that are constantly providing approvals to support projects across different stages of clinical trials. The majority of late-stage projects in Europe are receiving funds through EU grants. For instance, in July 2022, Achilles Therapeutics declared that it has been awarded a USD 4.2 million grant named ‘Horizon Europe’. It is the EU’s key funding initiative for research and innovation. This funding was awarded to advance personalized therapy manufacturing.

Stem cell therapy is also increasingly gaining attention due to its applications in therapeutics for autoimmune and metabolic disorders. It plays an essential role in developing immunity in an individual to fight against various metabolic disorders. For instance, in May 2022, Sernova and Evotec entered into a collaboration for the development of cell therapy to be used for the treatment of insulin-dependent diabetes using induced pluripotent stem cells (iPSC)-based therapeutics.

In addition, automation in adult stem cells & cord blood processing and storage are the key technologies expected to positively influence the growth of the adult & cord blood cells market. Furthermore, key entities in the market are involved in collaborations to reprogram newborn stem cells from umbilical cord blood as well as tissue into induced pluripotent stem cells (iPSCs). These developments are expected to drive the growth of the market over the forecast period.

Therapy Type Insights

The autologous therapy segment dominated the market with a revenue share of 94.64% in the year 2022. This segment is also projected to exhibit faster growth during the forecast period. The growth in the segment is attributed to the high adoption of numerous CAR-T therapies owing to their favorable outcomes for the treatment of various types of cancers and genetic disorders.

The FDA has approved some of such therapies and their wider adoption is currently under progress. For instance, in February 2022, the U.S. FDA granted approval to a drug called ciltacabtagene autoleucel (Carvykti) for adult subjects with multiple myeloma. This drug aims to treat the illness that is irresponsive to refractory therapeutics or that has relapsed after therapeutics.

The allogenic cell therapy segment is estimated to register substantial growth in the global cell therapy industry from 2023 to 2030. The growth can be attributed to its high adoption for designing novel therapeutic regimes. There are 542 active allogenic CAR-T agents in the global pipeline with many of them yielding favorable outcomes. For instance, Adaptimmune Ltd. collaborates with Genentech to focus on the utility of allogeneic therapies derived from iPSCs to create T-cells with higher proliferation capacity than mature T-cells.

Therapeutic Area Insights

The oncology segment dominated the overall market with the largest revenue share of 38.23% in 2022. CAR T-cells targeting CD19 reportedly provide high rates of complete and long-lasting remissions for patients with Acute lymphocytic leukemia (ALL). Furthermore, increasing FDA approval for novel therapies is expected to create growth opportunities in the cell therapy industry.

For instance, in October 2021, the U.S. FDA approved the use of the brexucabtagene autoleucel (Tecartus), a CAR-T therapy for individuals with B-cell precursor ALL who have not responded to prior treatment (refractory) or whose condition has returned after treatment. With this approval, brexucabtagene became the first CAR-T treatment for adults with ALL.

The musculoskeletal disorders area is expected to generate significant market growth in the coming years. Creating technologies that facilitate the regeneration or repair of damaged musculoskeletal tissues is the subject of extensive research. Various research groups analyze clinically applicable cell types utilized in therapies to cure musculoskeletal tissue degeneration and apply engineered or native skeletal progenitor cells to directly trigger tissue repair and rejuvenate musculoskeletal tissues.

Regional Insights

North America accounted for the largest cell therapy market share of 65.15% in 2022. This is attributed to the collaborative research initiatives by research institutes and pharmaceutical giants in the region. There are emerging advancements in the region through numerous collaborations. For instance, in June 2022, Immatics collaborated with Bristol Myers Squibb to develop Gamma Delta Allogeneic Cell Therapy Programs. Under this initiative, Immatics and Bristol Myers will create two programs possessed by Bristol Myers Squibb and both firms have the option to create up to four further programs each.

Asia Pacific is estimated to register the fastest CAGR of 12.33% during the forecast period due to increased demand for cell therapy in the region. Certain factors such as increasing awareness about novel therapies, growing investments, and expected favorable policies by governments are estimated to accelerate market growth during the forecast period. For instance, in June 2022, Tessa Therapeutics Ltd. raised USD 126 million through series funding to catalyze the development of next-generation cancer therapy.

Key Companies & Market Share Insights

Key companies in the market are undertaking various initiatives for the expansion of their customer base, by promoting it to surgeons for usage in transplantation procedures. Moreover, these companies are undertaking initiatives such as new product launches, collaborations, partnerships, mergers, and acquisitions to strengthen their market position. For instance, in January 2023, 2seventy bio and Regeneron entered into an expanded translational collaboration to generate new cell therapy-based combinations for solid tumors.

Moreover, in September 2021, Adaptimmune Therapeutics plc declared a collaboration with Genentech for the development and marketing of allogeneic therapies to be used for the treatment of multiple oncology variant indications. Some prominent players in the global cell therapy market include:

• Novartis AG

• Gilead Sciences, Inc.

• Bristol-Myers Squibb Company

• Johnson & Johnson Services, Inc

• JCR Pharmaceuticals Co., Ltd.

• Tego Science

• Atara Biotherapeutics

• Takeda Pharmaceutical Company Limited

• Bluebird Bio, Inc.

• Dendreon Corp.

Recent Development

• In January 2023, Kite, a Gilead Company entered into a strategic collaboration with Arcellx, Inc. to jointly develop and commercialize CART-ddBCMA for the treatment of relapsed multiple myeloma.

• In June 2023, Bristol Myers Squibb received FDA approval for its newly launched state-of-the-art cell therapy production facility in Devens, Massachusetts. The expansion is estimated to support BMS’ global cell therapy manufacturing footprint and fuel the long-term supply of its cell therapy products.

• In April 2023, Bristol Myers Squibb collaborated with Novartis to strengthen cell therapy capabilities by introducing a U.S. manufacturing facility for viral vector production of CAR T cell therapies.

• In December 2022, Kite acquired Acquire Tmunity Therapeutics to develop Next-Generation CAR T-Cell therapies in cancer treatment. Kite will gain access to pre-clinical and clinical projects and a 'armored' CAR T technology platform that may be applied to a range of CAR Ts to improve anti-tumor efficacy and quick production procedures as a result of the acquisition.

• In June 2022, Novartis collaborated with the American Society of Hematology to provide standard-of-care screening practices and improve the existing therapies for sickle cell disease in Sub-Saharan Africa

• In May 2022, the FDA approved Novartis Kymriah® CAR-T cell therapy for patients with relapsed or refractory follicular lymphoma.

• In April 2022, Kite expanded its CAR T-Cell Therapy development operations in Maryland and received FDA approval for commercial CAR T-cell therapy manufacturing for blood cancer.

Cell Therapy Market Report Scope

Global Cell Therapy Market Segmentation

This report forecasts revenue growth at global, regional, & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global cell therapy market report based on therapy type, therapeutic area, and region:

• Therapy Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Allogeneic Therapies

    • Stem Cell Therapies

      • Hematopoietic Stem Cell Therapies

      • Mesenchymal Stem Cell Therapies

    • Non-Stem Cell Therapies

      • Keratinocytes & Fibroblast-based Therapies

      • Others

  • Autologous Therapies

    • Stem Cell Therapies

      • BM, Blood, & Umbilical Cord-derived Stem Cells

      • Adipose derived cells

      • Others

    • Non-Stem Cell Therapies

      • T-Cell Therapies

        • CAR T Cell Therapy

        • T Cell Receptor (TCR)-based

      • Others

• Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)

  • Oncology

  • Cardiovascular Disease (CVD)

  • Musculoskeletal Disorders

  • Dermatology

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • Switzerland

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

  • Rest of the World